SCHEMBL2918822

SCHEMBL2918822

CC(=O)Nc1ccc2nc(CO)ccc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.59
▸ RAB9A P51151 8/20 0.59
▸ NPC1 O15118 6/20 0.59
▸ MEN1 O00255 4/20 0.59
▸ KMT2A Q03164 4/20 0.59
▸ MAPT P10636 3/20 0.59
▸ GLA P06280 1/20 0.59
▸ TNNI3 P19429 1/20 0.59
▸ TNNT2 P45379 1/20 0.59
▸ TNNC1 P63316 1/20 0.59
▸ RUNX1 Q01196 1/20 0.59
▸ CBFB Q13951 1/20 0.59
▸ PABPC1 P11940 1/20 0.53
▸ ATM Q13315 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.49
▸ ELANE P08246 1/20 0.48
▸ LDHA P00338 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ ROCK2 O75116 1/20 0.46
▸ ROCK1 Q13464 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13177201 0.87 KDM4E (0.58) KDM4ERAB9ANPC1MEN1KMT2A
Hydrochloric Acid SCHEMBL2921145 0.85 KDM4E (0.56) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL2927953 0.84 KDM4E (0.55) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL2921048 0.81 KDM4E (0.51) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL2926846 0.80 MCHR1 (0.65) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL2175124 0.80 NPC1 (0.67) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL17432454 0.80 KDM4E (0.65) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL2922304 0.79 MCHR1 (0.64) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL13594195 0.78 KDM4E (0.63) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL2923647 0.78 KDM4E (0.52) KDM4ERAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 — — EP disclosed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 — — EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 — — US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 — — US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 KDM4E 2403/4885RAB9A 1132/4885NPC1 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback